L-glutamine Schiff base copper complex as a proteasome inhibitor and an apoptosis inducer in human cancer cells.
Interest in the use of metallic compounds for cancer treatment has been increasing since the discovery of cisplatin. Clinical studies suggest the use of proteasome inhibitors as potential novel anticancer agents. L-glutamine is the most abundant free amino acid in the body, and has been shown to play a regulatory role in several cellular processes, including metabolism, degradation, redox potential and cellular integrity. Although glutamine is reported to play a role in the regulation of apoptosis, the effect of glutamine copper complex on tumor cells and the involved molecular mechanism have not been investigated. Here, for the first time, we report that a newly synthesized L-glutamine-containing copper complex has proteasome-inhibitory activity in human breast cancer and leukemia cells. The inhibition of the tumor proteasomal activity results in the accumulation of ubiquitinated proteins and ubiquitinated form of IkappaB-alpha, a natural proteasome substrate, followed by induction of apoptosis. Furthermore, this glutamine Schiff base copper complex selectively inhibits the proteasomal activity and induces cell death in cultured breast cancer cells, but not normal, immortalized breast cells. Our data suggest that glutamine Schiff base copper complexes have a potential use for to be used in cancer treatment and prevention.
Xiao
Yan
Y
Key Laboratory of Marine Chemistry Theory and Technology, Ministry of Education, College of Chemistry and Chemical Engineering, Ocean University of China, Qingdao, PR China.
Bi
Caifeng
C
Fan
Yuhua
Y
Cui
Cindy
C
Zhang
Xia
X
Dou
Q Ping
QP
D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D001943:Breast Neoplasms / Q000201:enzymology / Q000473:pathology*; D049109:Cell Proliferation / Q000187:drug effects; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005973:Glutamine / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D020672:I-kappa B Proteins / Q000378:metabolism; D019169:Jurkat Cells; D007700:Kinetics; D015458:Leukemia, T-Cell / Q000201:enzymology / Q000473:pathology*; D000072000:NF-KappaB Inhibitor alpha; D009942:Organometallic Compounds / Q000494:pharmacology*; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D061988:Proteasome Inhibitors; D025801:Ubiquitin / Q000378:metabolism
D000970:Antineoplastic Agents; D015853:Cysteine Proteinase Inhibitors; D020672:I-kappa B Proteins; C533573:L-glutamine-o-vanillin-copper; C000606204:NFKBIA protein, human; D009942:Organometallic Compounds; D061988:Proteasome Inhibitors; D025801:Ubiquitin; D005973:Glutamine; D000072000:NF-KappaB Inhibitor alpha; D046988:Proteasome Endopeptidase Complex